Crescent Biopharma (NASDAQ:CBIO) Insider Sells 658 Shares of Stock

Crescent Biopharma, Inc. (NASDAQ:CBIO) insider Jan Pinkas sold 658 shares of the stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $17.90, for a total value of $11,778.20. Following the transaction, the insider directly owned 21,581 shares in the company, valued at approximately $386,299.90. This represents a 2.96% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jan Pinkas also recently made the following trade(s):

• On Monday, June 22nd, Jan Pinkas sold 1,288 shares of Crescent Biopharma stock. The shares were sold at an average price of $17.99, for a total value of $23,171.12.

Crescent Biopharma Stock Performance

Crescent Biopharma stock traded up $0.12 during trading on Friday, hitting $16.89. The company’s stock had a trading volume of 3,123,507 shares, compared to its average volume of 294,314. The stock has a market capitalization of $627.36 million, a price-to-earnings ratio of -2.51 and a beta of 1.24. The stock’s fifty day moving average is $17.12 and its 200 day moving average is $17.43. Crescent Biopharma, Inc. has a 1-year low of $8.72 and a 1-year high of $27.41.

Crescent Biopharma (NASDAQ:CBIO) last issued its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported ($0.74) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.74). On average, research analysts anticipate that Crescent Biopharma, Inc. will post -2.91 EPS for the current fiscal year.

Key Crescent Biopharma News

Here are the key news stories impacting Crescent Biopharma this week:

• Neutral Sentiment: CEO Joshua Brumm, COO Jonathan McNeill, CFO Richard Scalzo, and other insiders collectively sold 16,726 shares worth approximately $285,501 between September 16 and September 18. The sales reduced individual holdings by roughly 0.5% to 3.2%, but insiders continued to retain meaningful positions. SEC insider transaction filing
• Neutral Sentiment: All reported transactions were executed under pre-arranged Rule 10b5-1 trading plans and were described as sales to cover tax-withholding obligations tied to vested equity awards. That reduces the likelihood that the transactions represent a change in management’s outlook, although the aggregate selling may still weigh modestly on sentiment. SEC insider transaction filing
• Negative Sentiment: The concentration of sales by senior executives—including the CEO and COO—could be viewed as a near-term supply or sentiment overhang. However, the relatively small percentage reductions and tax-related rationale make this a limited negative signal rather than a clear indication of weakening business prospects. SEC insider transaction filing

Institutional Trading of Crescent Biopharma

A number of institutional investors have recently modified their holdings of the company. Opaleye Management Inc. increased its position in Crescent Biopharma by 0.5% during the 2nd quarter. Opaleye Management Inc. now owns 1,319,351 shares of the biopharmaceutical company’s stock worth $23,748,000 after purchasing an additional 6,736 shares in the last quarter. Squarepoint Ops LLC purchased a new position in Crescent Biopharma in the second quarter valued at approximately $435,000. Wellington Management Group LLP acquired a new position in Crescent Biopharma during the second quarter valued at approximately $263,000. Stonepine Capital Management LLC acquired a new position in Crescent Biopharma during the second quarter valued at approximately $720,000. Finally, Bank of America Corp DE purchased a new stake in Crescent Biopharma during the second quarter worth approximately $465,000. Hedge funds and other institutional investors own 75.19% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the stock. HC Wainwright restated a “neutral” rating on shares of Crescent Biopharma in a report on Thursday, July 16th. TD Cowen upgraded shares of Crescent Biopharma to a “strong-buy” rating in a report on Monday, August 24th. Wedbush reissued an “outperform” rating and set a $27.00 price objective on shares of Crescent Biopharma in a research note on Monday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Crescent Biopharma in a report on Friday, August 7th. Two equities research analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Crescent Biopharma presently has an average rating of “Moderate Buy” and an average price target of $29.60.

Crescent Biopharma Company Profile

Crescent Biopharma, Inc (NASDAQ: CBIO) is a biopharmaceutical company focused on discovering and developing innovative therapies for the treatment of serious diseases. The company’s activities center on research, preclinical development and clinical evaluation of investigational drug candidates.

Crescent Biopharma does not appear to have commercially marketed products. Its pipeline consists of experimental therapies intended to address significant unmet medical needs, although detailed information about specific candidates, therapeutic areas and development stages may be limited in publicly available sources.

The company is headquartered in the United States and serves the biopharmaceutical market through its drug-development programs and potential future partnerships.